SB 689 of the 2004 Regular Session and HB 369 of the 2005 Regular Session required LDH to provide an annual written report to the governor and to the legislature regarding the cost of administering the preferred drug list, including the cost of administering the prior authorization function, the costs of development and maintenance of the preferred drug list and aggregate funds returned to the federal government related to pharmaceutical rebates, and an analysis of the utilization trends for medical services provided by the state and any correlation to the preferred drug list.